Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer

Tatsuya Yoshida, Yuko Oya, Kosuke Tanaka, Junichi Shimizu, Yoshitsugu Horio, Hiroaki Kuroda, Yukinori Sakao, Toyoaki Hida, Yasushi Yatabe

Research output: Contribution to journalArticlepeer-review

233 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases